Somatosensory cortex and central amygdala regulate neuropathic pain-mediated peripheral immune response via vagal projections to the spleen

Nature Neuroscience, Journal Year: 2024, Volume and Issue: 27(3), P. 471 - 483

Published: Jan. 30, 2024

Language: Английский

---

Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis

Multiple Sclerosis Journal, Journal Year: 2023, Volume and Issue: 29(4-5), P. 585 - 594

Published: Feb. 1, 2023

Background Data are sparse regarding the safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with multiple sclerosis (MS). Objective To estimate (1) pooled proportion MS experiencing relapse among vaccine recipients; (2) rate transient neurological worsening, adverse events, and serious events; (3) previous outcomes interest for different SARS-CoV-2 types. Methods Systematic review meta-analysis pharmacovigilance registries observational studies. Results Nineteen studies comprising 14,755 who received 23,088 doses COVID-19 were included. Mean age was 43.3 years (95% confidence interval (CI): 40–46.6); relapsing-remitting, secondary-progressive, primary-progressive clinically isolated diagnosed 82.6% CI: 73.9–89.8), 12.6% 6.3–20.8), 6.7% 4.2–9.9), 2.9% 1–5.9) cases, respectively. The at a mean time 20 days 12–28.2) from vaccination 1.9% 1.3%–2.6%; I = 78%), risk being independent type administered SARS-CoV-2-vaccine ( p subgroup differences 0.7 messenger RNA (mRNA), inactivated virus, adenovector-based vaccines). After vaccination, worsening observed 4.8% 2.3%–8.1%) patients. Adverse events reported 52.8% 46.7%–58.8%) 0.1% 0%–0.2%) vaccinations, Conclusion does not appear to increase MS. Weighted against risks SARS-CoV-2-related complications exacerbations, these data provide compelling pro-vaccination arguments

Language: Английский

---

ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

Multiple Sclerosis Journal, Journal Year: 2023, Volume and Issue: 29(8), P. 904 - 925

Published: June 9, 2023

Background: With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of risk management strategy Objective: To develop a European evidence-based consensus pwMS who are candidates disease-modifying therapies (DMTs). Methods: This work was conducted by multidisciplinary working group using formal methodology. Clinical questions (defined as population, interventions, and outcomes) considered all authorized DMTs vaccines. A systematic literature search quality evidence defined according to Oxford Centre Evidence-Based Medicine Levels Evidence. The recommendations were formulated based on risk–benefit balance. Results: Seven questions, encompassing vaccine safety, effectiveness, global in sub-populations (pediatric, pregnant women, elderly international travelers) considered. narrative description considering published studies, guidelines, position statements is presented. total 53 agreed after three rounds consensus. Conclusion: first proposes best current expert knowledge, goal homogenizing immunization practices pwMS.

Language: Английский

---

The CXCL13 index biomarker predicts success or failure of moderate-efficacy disease-modifying therapies in multiple sclerosis; a real-world study

Multiple Sclerosis and Related Disorders, Journal Year: 2025, Volume and Issue: unknown, P. 106303 - 106303

Published: Jan. 1, 2025

Language: Английский

---

Engineered immunological niche directs therapeutic development in models of progressive multiple sclerosis

Proceedings of the National Academy of Sciences, Journal Year: 2025, Volume and Issue: 122(7)

Published: Feb. 12, 2025

Primary progressive multiple sclerosis (MS) is a demyelinating autoimmune disease with only single class of FDA-approved treatment, B cell depletion. Novel treatments could emerge from deeper understanding the interplay between types within diseased tissue throughout progression. We initially describe an engineered biomaterial–based immunological niche (IN) as surrogate for to investigate immune function and phenotype dynamics chronic mouse model MS. Using these niches, we identify array dysregulated CC chemokine signaling potential targets. then develop antigen-loaded nanoparticles that reduce signaling, while delivering antigen. These serve antigen-specific injection reduces burden, even if administered after symptomatic onset. This report demonstrates proof principle biomaterial scaffold can monitor function, drug targets, guide development therapeutic.

Language: Английский

---

Vaccination in multiple sclerosis: Tackling challenges and paving the way for effective immunization

Multiple Sclerosis Journal, Journal Year: 2025, Volume and Issue: unknown

Published: March 12, 2025

Background: Vaccination in patients with multiple sclerosis (PwMS) presents unique challenges. Disease-modifying therapies (DMTs) can increase infectious risks, though these are largely preventable through immunizations. However, DMTs also reduce vaccine efficacy. Aims: This study aimed to identify challenges achieving effective immunization for PwMS and explore strategies optimize vaccination practices. Methods: Recent guidelines studies on were reviewed pinpoint challenges, unmet needs, opportunities improvement. Results: Early before DMT initiation is vital optimal responses, coordinating vaccinations DMTs’ Strategies enhance efficacy, such as bridging or more immunogenic formulations, may benefit highly active requiring immediate initiation. Although live-attenuated vaccines pose those immunosuppressive therapies, emerging evidence suggests safe administration select cases. Overcoming hesitancy demands targeted education, personalized counseling, improved access services, especially low- middle-income countries. Inclusivity crucial, particularly groups, pediatric, pregnant, elderly PwMS. Conclusion: A multifaceted approach essential addressing Collaborative efforts involving stakeholders crucial overcoming obstacles generating robust evidence. We propose an integrated strategy ensure while maintaining timely administration.

Language: Английский

---

Multiple sclerosis and COVID-19: interactions and unresolved issues

The Lancet Neurology, Journal Year: 2025, Volume and Issue: 24(4), P. 361 - 370

Published: March 20, 2025

Language: Английский

---

B cell targeted therapies in inflammatory autoimmune disease of the central nervous system

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: March 9, 2023

Cumulative evidence along several lines indicates that B cells play an important role in the pathological course of multiple sclerosis (MS), neuromyelitisoptica spectrum disorders (NMOSD) and related CNS diseases. This has prompted extensive research exploring utility targeting to contain disease activity these disorders. In this review, we first recapitulate development from their origin bone marrow migration periphery, including expression therapy-relevant surface immunoglobulin isotypes. Not only ability produce cytokines immunoglobulins seems be essential driving neuroinflammation, but also regulatory functions strongly impact pathobiology. We then critically assess studies cell depleting therapies, CD20 CD19 monoclonal antibodies, as well new class modulating substances, Bruton´s tyrosinekinase (BTK) inhibitors, MS, NMOSD MOGAD.

Language: Английский

---

A Comprehensive Review on Neuroimmunology: Insights from Multiple Sclerosis to Future Therapeutic Developments

Biomedicines, Journal Year: 2023, Volume and Issue: 11(9), P. 2489 - 2489

Published: Sept. 8, 2023

This review delves into neuroimmunology, focusing on its relevance to multiple sclerosis (MS) and potential treatment advancements. Neuroimmunology explores the intricate relationship between immune system central nervous (CNS). Understanding these mechanisms is vital for grasping pathophysiology of diseases like MS devising innovative treatments. introduces foundational neuroimmunology concepts, emphasizing role cells, cytokines, blood–brain barrier in CNS stability. It highlights how their dysregulation can contribute discusses genetic environmental factors influencing susceptibility. Cutting-edge research methods, from omics techniques advanced imaging, have revolutionized our understanding MS, offering valuable diagnostic prognostic tools. also touches intriguing gut–brain axis, examining gut microbiota impacts neuroimmunological processes therapeutic implications. Current treatments, immunomodulatory drugs disease-modifying therapies, are discussed alongside promising experimental approaches. The personalized medicine, cell-based gene therapy management explored. In conclusion, this underscores neuroimmunology’s significance research, suggesting that a deeper could pave way more tailored effective treatments similar conditions. Continued collaboration essential enhancing patient outcomes.

Language: Английский

---

European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

European Journal of Neurology, Journal Year: 2023, Volume and Issue: 30(8), P. 2144 - 2176

Published: June 9, 2023

Abstract Background and purpose With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of risk management strategy. We aimed to develop a European evidence‐based consensus strategy pwMS who are candidates disease‐modifying therapies (DMTs). Methods This work was conducted by multidisciplinary working group using formal methodology. Clinical questions (defined as population, interventions outcomes) considered all authorized DMTs vaccines. A systematic literature search quality evidence defined according Oxford Centre Evidence‐Based Medicine Levels Evidence. The recommendations were formulated based on risk–benefit balance. Results Seven questions, encompassing vaccine safety, effectiveness, global in subpopulations (pediatric, pregnant women, elderly international travelers) considered. narrative description considering published studies, guidelines position statements is presented. total 53 agreed after three rounds consensus. Conclusion first proposes best current expert knowledge, goal homogenizing immunization practices pwMS.

Language: Английский

---